Actively Recruiting
Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
Led by Royal Marsden NHS Foundation Trust · Updated on 2025-07-01
16
Participants Needed
1
Research Sites
42 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
CONDITIONS
Official Title
Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male aged 18 years or older
- Biopsy confirmed first or recurrent metastatic melanoma with palpable nodal disease
- Have undergone staging FDG PET-CT scan as part of routine care
- Scheduled for surgery to remove the primary melanoma site
You will not qualify if you...
- Unable to provide voluntary written informed consent
- Unwilling to complete all study assessments
- Female patients
- Receiving androgen deprivation therapy or androgen receptor antagonist treatments
- Current or prior diagnosis of prostate cancer
- Received Lu-177 PSMA therapy or barium studies within 10 days before PSMA PET-CT scan
- Not fluent in English
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Royal Marsden NHS Foundation Trust
London, United Kingdom, SW3 6JJ
Actively Recruiting
Research Team
R
Reyhaneh Sadegh Zadeh
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here